Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) went up by 0.67% from its latest closing price compared to the recent 1-year high of $306.08. The company’s stock price has collected 3.15% of gains in the last five trading sessions. Press Release reported on 09/25/20 that FDA Approves KALYDECO(R) (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Is It Worth Investing in Vertex Pharmaceuticals Incorporated (NASDAQ :VRTX) Right Now?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) scored a price-to-earnings ratio above its average ratio, recording 34.39 x from its present earnings ratio. Plus, the 36-month beta value for VRTX is at 0.79. Opinions of the stock are interesting as 18 analysts out of 26 who provided ratings for Vertex Pharmaceuticals Incorporated declared the stock was a “buy,” while 0 rated the stock as “overweight,” 8 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $307.41, which is $34.31 above the current price. VRTX currently public float of 260.09M and currently shorts hold a 1.17% ratio of that float. Today, the average trading volume of VRTX was 1.30M shares.
VRTX’s Market Performance
VRTX stocks went up by 3.15% for the week, with a monthly drop of -2.51% and a quarterly performance of -4.95%, while its annual performance rate touched 62.38%. The volatility ratio for the week stands at 2.41% while the volatility levels for the past 30 days are set at 3.09% for Vertex Pharmaceuticals Incorporated. The simple moving average for the period of the last 20 days is 2.16% for VRTX stocks with a simple moving average of 6.05% for the last 200 days.
Analysts’ Opinion of VRTX
Many brokerage firms have already submitted their reports for VRTX stocks, with H.C. Wainwright repeating the rating for VRTX by listing it as a “Buy.” The predicted price for VRTX in the upcoming period, according to H.C. Wainwright is $315 based on the research report published on July 31st of the current year 2020.
Morgan Stanley, on the other hand, stated in their research note that they expect to see VRTX reach a price target of $300. The rating they have provided for VRTX stocks is “Equal-Weight” according to the report published on July 08th, 2020.
H.C. Wainwright gave a rating of “Buy” to VRTX, setting the target price at $295 in the report published on April 30th of the current year.
VRTX Trading at 0.27% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.10% of loss for the given period.
Volatility was left at 3.09%, however, over the last 30 days, the volatility rate increased by 2.41%, as shares sank -1.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.62% lower at present.
During the last 5 trading sessions, VRTX rose by +3.15%, which changed the moving average for the period of 200-days by +24.27% in comparison to the 20-day moving average, which settled at $266.20. In addition, Vertex Pharmaceuticals Incorporated saw 24.28% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRTX starting from Silva Paul M, who sale 1,078 shares at the price of $271.17 back on Aug 06. After this action, Silva Paul M now owns 14,932 shares of Vertex Pharmaceuticals Incorporated, valued at $292,319 using the latest closing price.
ALTSHULER DAVID, the EVP, Global Research and CSO of Vertex Pharmaceuticals Incorporated, sale 1,223 shares at $271.19 during a trade that took place back on Aug 06, which means that ALTSHULER DAVID is holding 28,902 shares at $331,663 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- +28.31 for the present operating margin
- +86.74 for the gross margin
The net margin for Vertex Pharmaceuticals Incorporated stands at +28.49. The total capital return value is set at 19.85, while invested capital returns managed to touch 20.07. Equity return is now at value 32.90, with 23.80 for asset returns.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Based on Vertex Pharmaceuticals Incorporated (VRTX), the company’s capital structure generated 11.06 points at debt to equity in total, while total debt to capital is 9.96. Total debt to assets is 8.09, with long-term debt to equity ratio resting at 10.24. Finally, the long-term debt to capital ratio is 9.22.
Currently, EBITDA for the company is 747.56M with total debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 13.06, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 7.88 and the total asset turnover is 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.61.
